Bio Plus Co

Bio Plus Co Financing Cash Flow

The Net Financing Cash Flow of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 53.72 B KRW. In the previous year, Net Financing Cash Flow was -10.21 B KRW — a change of -626.03% (higher).

Financing Cash Flow

53.72 BKRW

YoY

-626.03%

Last updated:

Net Financing Cash Flow of Bio Plus Co is 2024 53.72 B KRW. Net Financing Cash Flow of Bio Plus Co was 2023 -10.21 B KRW. It decreases by -626.03% higher compared to the previous year.

The Bio Plus Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
1.63 B KRW
Jan 1, 2019
-126.32 M KRW
Jan 1, 2020
4.83 B KRW
Jan 1, 2021
34.04 B KRW
Jan 1, 2022
30.66 B KRW
Jan 1, 2023
-10.21 B KRW
Jan 1, 2024
53.72 B KRW
The Bio Plus Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
53.72 BKRW-626.03%
-10.21 BKRW-133.31%
30.66 BKRW-9.94%
34.04 BKRW+605.32%
4.83 BKRW-3,921.07%
-126.32 MKRW-107.75%
1.63 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Net Financing Cash Flow of Bio Plus Co is 53.72 B KRW in 2024.

Net Financing Cash Flow of Bio Plus Co changed from -10.21 B KRW to 53.72 B KRW, representing a -626.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co